MASS on XNAS, Technology, 908 Devices Inc., job postings
Measures activity, not value. Not investment advice.
September quarter revenue rose 35% to $18.9M but the stock fell 27% in a month.
BadInsiders sold $2.5M in 90 days and bought nothing
BadNet loss of $24.3M over 12 months despite 14% revenue growth
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.
expected around 19 Jan 2027 (an estimate: a year ago it reported on 20 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $18.9M, net loss $4.6M.
31 Dec 2021RevenueNet incomeNet losstallest bar $43.6M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$18.9M
-$4.6M
30 Jun 2026
$16.1M
-$11.9M
31 Mar 2026
$13.4M
-$12.0M
31 Dec 2025
–
$4.2M
30 Sep 2025
$14.0M
-$15.0M
30 Jun 2025
$13.0M
-$13.3M
31 Mar 2025
$11.8M
$43.6M
31 Dec 2024
$18.8M
-$19.4M
30 Sep 2024
$16.8M
-$29.3M
30 Jun 2024
$14.0M
-$12.5M
31 Mar 2024
$10.0M
-$10.9M
31 Dec 2023
$14.4M
-$7.4M
30 Sep 2023
$14.3M
-$7.1M
30 Jun 2023
$12.1M
-$9.3M
31 Mar 2023
$9.5M
-$12.5M
31 Dec 2022
$11.6M
-$9.8M
30 Sep 2022
$15.8M
-$6.3M
30 Jun 2022
$11.1M
-$8.1M
31 Mar 2022
$8.3M
-$9.4M
31 Dec 2021
$15.8M
–
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$65.8M
$57.6M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+14%
+5.0%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$24.3M
-$4.1M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$0.64
-$0.11
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
52.3%
49.2%
49.6%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-42.7%
-109%
-7.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-36.9%
-7.2%
-10.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-17.0%
-17.0%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$2.6M
-$28.4M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$99.1M
$112.1M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$99.1M (net cash)
-$112.1M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.45
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$3.60
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
33.4
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
5.5
4.1
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
4.0
4.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
2.4
2.4
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+35%
$18.9M vs $14.0M (quarter ended 30 Sep 2026)
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$2.5M
bought $0, sold $2.5M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+6.2%
119 13F filers vs 112
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
87%
36.2M shares held by 13F filers (30 Sep 2026) of 41.6M outstanding (6 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
6.1%
2.5M shares sold short (30 Oct 2026) of 41.6M outstanding (6 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
7.1
2.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-6.0%
2.7M shares sold short in the report before, 2.5M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
67%
67% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 61%
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$30K
the 12 months before: $15K
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$290K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
10
10 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
10 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Price $8.67 on 20 Nov 2026, +52% over 12 months (12-month range $5.09 to $12.87)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $10.3M in the last 12 months (the 12 months before: -$242K).Revenue per quarter. Revenue $18.9M in the latest quarter, +35% on a year earlier.Capital spending per quarter. Capital spending $65K in the latest quarter, -90% on a year earlier.Institutional holders (13F filers). 119 13F filers reported holding it in the latest 13F quarter, +17% on a year earlier.Federal obligations. Federal obligations: $11K published in the last 12 months, -70% on the 12 months before.Lobbying spend. Lobbying spend: $290K published in the last 12 months, 0% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, workers in warn layoff notices.
Quarter ended 31 Dec 2020: $5.7M; public on 12 Mar 2022
Quarter ended 31 Dec 2021: $15.8M, +177% on a year earlier; public on 12 Mar 2022
Quarter ended 31 Mar 2022: $8.3M, +50% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $11.1M, +34% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $15.8M, +26% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $11.6M, -27% on a year earlier; public on 16 Mar 2023
Quarter ended 31 Mar 2023: $9.5M, +14% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $12.1M, +8.9% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $14.3M, -9.5% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $14.4M, +23% on a year earlier; public on 9 Mar 2024
Quarter ended 31 Mar 2024: $10.0M, +5.3% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $14.0M, +16% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $16.8M, +17% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $18.8M, +31% on a year earlier; public on 8 Mar 2025
Quarter ended 31 Mar 2025: $11.8M, +18% on a year earlier; public on 14 May 2025
Quarter ended 30 Jun 2025: $13.0M, -7.2% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $14.0M, -17% on a year earlier; public on 11 Nov 2025
Quarter ended 31 Mar 2026: $13.4M, +14% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $16.1M, +23% on a year earlier; public on 12 Aug 2026
Quarter ended 30 Sep 2026: $18.9M, +35% on a year earlier; public on 11 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $54K; public on 12 Mar 2022
Quarter ended 31 Mar 2022: $617K, +6756% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $72K; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $744K, +1183% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $612K, +1033% on a year earlier; public on 16 Mar 2023
Quarter ended 31 Mar 2023: $1.2M, +92% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $320K, +344% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $207K, -72% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $333K, -46% on a year earlier; public on 9 Mar 2024
Quarter ended 30 Sep 2024: $156K, -25% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $190K, -43% on a year earlier; public on 8 Mar 2025
Quarter ended 31 Mar 2025: $159K; public on 14 May 2025
Quarter ended 30 Jun 2025: $122K; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $680K, +336% on a year earlier; public on 11 Nov 2025
Quarter ended 31 Mar 2026: $40K, -75% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $162K, +33% on a year earlier; public on 12 Aug 2026
Quarter ended 30 Sep 2026: $65K, -90% on a year earlier; public on 11 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 81; public on 14 Feb 2022
31 Mar 2022 report: 83; public on 16 May 2022
30 Jun 2022 report: 74; public on 15 Aug 2022
30 Sep 2022 report: 76; public on 14 Nov 2022
31 Dec 2022 report: 85; public on 14 Feb 2023
31 Mar 2023 report: 79; public on 15 May 2023
30 Jun 2023 report: 77; public on 14 Aug 2023
30 Sep 2023 report: 78; public on 14 Nov 2023
31 Dec 2023 report: 75; public on 14 Feb 2024
31 Mar 2024 report: 69; public on 15 May 2024
30 Jun 2024 report: 87; public on 14 Aug 2024
30 Sep 2024 report: 82; public on 14 Nov 2024
31 Dec 2024 report: 79; public on 14 Feb 2025
31 Mar 2025 report: 87; public on 15 May 2025
30 Jun 2025 report: 97; public on 14 Aug 2025
30 Sep 2025 report: 102; public on 14 Nov 2025
31 Dec 2025 report: 113; public on 17 Feb 2026
31 Mar 2026 report: 108; public on 15 May 2026
30 Jun 2026 report: 112; public on 14 Aug 2026
30 Sep 2026 report: 119; public on 16 Nov 2026
Federal obligations
Month from 1 Apr 2022: $13K published
Month from 1 Jul 2022: $192K published
Month from 1 Sep 2022: $7K published
Month from 1 Apr 2023: $44K published
Month from 1 May 2023: $86K published
Month from 1 Jun 2023: $0 published
Month from 1 Aug 2023: $7K published
Month from 1 Sep 2023: $96K published
Month from 1 Oct 2023: $7K published
Month from 1 Nov 2023: -$0.0 published
Month from 1 Dec 2023: $0 published
Month from 1 Mar 2024: $52K published
Month from 1 Apr 2024: $11K published
Month from 1 Jun 2024: -$52K published
Month from 1 Jul 2024: $48K published
Month from 1 Feb 2025: $0 published
Month from 1 May 2025: $15K published
Month from 1 Aug 2025: $12K published
Month from 1 Sep 2025: $10K published
Month from 1 Oct 2025: $0 published
Month from 1 Apr 2026: $8K published
Month from 1 Aug 2026: $4K published
Lobbying spend
Quarter from 1 Jan 2022: $40K published
Quarter from 1 Apr 2022: $40K published
Quarter from 1 Jul 2022: $40K published
Quarter from 1 Oct 2022: $40K published
Quarter from 1 Jan 2023: $40K published
Quarter from 1 Apr 2023: $50K published
Quarter from 1 Jul 2023: $50K published
Quarter from 1 Oct 2023: $50K published
Quarter from 1 Jan 2024: $50K published
Quarter from 1 Apr 2024: $60K published
Quarter from 1 Jul 2024: $60K published
Quarter from 1 Oct 2024: $72K published
Quarter from 1 Jan 2025: $72K published
Quarter from 1 Apr 2025: $72K published
Quarter from 1 Jul 2025: $72K published
Quarter from 1 Oct 2025: $72K published
Quarter from 1 Jan 2026: $72K published
Quarter from 1 Apr 2026: $72K published
Quarter from 1 Jul 2026: $72K published
Quarter from 1 Oct 2026: $72K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $18.9M (30 Sep 2026), 1.4× its normal quarter; higher than 100% of its own history.
Reported lobbying spend: $72K in Q3 2026, $72K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Chemical Trace Detection issues; Chenmical Trace Detection issues; Providing Officers With Electronic Resources (POWER) Act, Chemical Trace Detection issues Grant relate dissuesHomeland security, Defense, LAW
had 2.6M shares sold short in the 15 May 2025 report, 2.5× the same report last year.
Same report last year: 1.0M; its normal report is 1.4M.
See the evidence
This period
2.6M (the 15 May 2025 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
182K
How far from its usual level
+4.6
Same report last year
1.0M
History used
1,596 days
the 15 May 2025 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.8M shares sold short in the 30 Apr 2025 report, 2.1× the same report last year.
Same report last year: 1.3M; its normal report is 1.4M.
See the evidence
This period
2.8M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
108K
How far from its usual level
+8.8
Same report last year
1.3M
History used
1,581 days
the 30 Apr 2025 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.8M shares sold short in the 15 Apr 2025 report, 2.3× the same report last year.
Same report last year: 1.2M; its normal report is 1.4M.
See the evidence
This period
2.8M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
108K
How far from its usual level
+9.2
Same report last year
1.2M
History used
1,566 days
the 15 Apr 2025 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.6M shares sold short in the 31 Mar 2025 report, 2.2× the same report last year.
Same report last year: 1.2M; its normal report is 1.4M.
See the evidence
This period
2.6M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
108K
How far from its usual level
+7.5
Same report last year
1.2M
History used
1,551 days
the 31 Mar 2025 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.8M shares sold short in the 14 Mar 2025 report, 2.7× the same report last year.
Same report last year: 1.1M; its normal report is 1.4M.
See the evidence
This period
2.8M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
108K
How far from its usual level
+9.3
Same report last year
1.1M
History used
1,534 days
the 14 Mar 2025 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.3M shares sold short in the 28 Feb 2025 report, 2.1× the same report last year.
Same report last year: 1.1M; its normal report is 1.3M.
See the evidence
This period
2.3M (the 28 Feb 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
108K
How far from its usual level
+5.7
Same report last year
1.1M
History used
1,520 days
the 28 Feb 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.3M shares sold short in the 14 Feb 2025 report, 2.0× the same report last year.
Same report last year: 1.1M; its normal report is 1.3M.
See the evidence
This period
2.3M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
108K
How far from its usual level
+5.9
Same report last year
1.1M
History used
1,506 days
the 14 Feb 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.9M shares sold short in the 31 Jan 2025 report, 1.5× the same report last year.
Same report last year: 1.3M; its normal report is 1.3M.
See the evidence
This period
1.9M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
93K
How far from its usual level
+4.3
Same report last year
1.3M
History used
1,492 days
the 31 Jan 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.9M shares sold short in the 15 Jan 2025 report, 1.3× the same report last year.
Same report last year: 1.4M; its normal report is 1.3M.
See the evidence
This period
1.9M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
92K
How far from its usual level
+4.3
Same report last year
1.4M
History used
1,476 days
the 15 Jan 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $15.8M for the quarter ended 31 Dec 2021, 2.8× the same quarter last year.
Same quarter last year: $5.7M; its normal quarter is $6.0M.
See the evidence
This period
$15.8M (the quarter ended 31 Dec 2021)
Normal quarter (median of 7 earlier)
$6.0M
Typical spread (median absolute deviation)
$2.0M
How far from its usual level
+3.2
Same quarter last year
$5.7M
History used
640 days
the quarter ended 31 Dec 20217 earlier quartersnormal: $6.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Showing the newest 40 of 58 entries; narrow the window or the kind of data to see older ones.
Not listed: 184 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001555279
Ticker
MASS
Domain
908devices.com
Employer name
908 Devices, Inc. (1 unverified)
Fein
45-4524096 (1 unverified)
Hq location
MA|BURLINGTON|01803 (1 unverified)
Lobbying client
908 devices
Name
908 Devices Inc., 908 Devices Securities Corporation, CAM2 Technologies, LLC, Company Name
Uei
W9F8K3F8LWU1
Wikidata
Q120997607
DOL H-1B labor condition applications and PERM certifications2 data points16 Dec 2024 to 16 Dec 2024
Federal lobbying disclosures (LDA)4 records, 69 data points15 Jan 2019 to 30 Sep 2026
SEC Form 13F institutional holdings216 data points31 Dec 2020 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)77 records15 Mar 2017 to 10 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)512 data points31 Dec 2019 to 6 Nov 2026
SEC Form 4 insider transactions143 records, 400 data points22 Dec 2020 to 6 Nov 2026
FINRA short interest (twice monthly)419 data points31 Dec 2020 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2976 data points18 Dec 2020 to 20 Nov 2026
USASpending.gov federal awards1 record, 171 data points7 Apr 2015 to 6 Aug 2026